MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

121.06
-1.69
-1.38%
After Hours: 121.15 +0.09 +0.07% 17:21 12/03 EST
OPEN
122.26
PREV CLOSE
122.75
HIGH
122.73
LOW
120.11
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
128.57
52 WEEK LOW
72.67
MARKET CAP
26.49B
P/E (TTM)
28.35
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Providence Therapeutics Announces Jared Davis as President
Providence Therapeutics Announces Jared Davis as President
CNW Group · 2d ago
Lookback: Miller Value Partners 2019 Alexion Pharmaceuticals (ALXN) Thesis
Insider Monkey · 3d ago
Alexion Granted Orphan Drug Designation For Ravulizumab For 'Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy'
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=783320
Benzinga · 11/25 15:24
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Zacks · 11/24 20:14
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("" or the ""), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives notice of an Extraordinary General Meeting (EGM) of shareholders to be held on December 17, 2020.
ACCESSWIRE · 11/23 06:20
Benzinga's Top Upgrades, Downgrades For November 20, 2020
Upgrades * According to Canaccord Genuity, the prior rating for Spirit AeroSystems Holdings Inc (NYSE: SPR) was changed from Hold to Buy. In the third quarter, Spirit AeroSystems Hldgs showed an EPS of $1.34, compared to $1.62 from the year-ago quarter. The stock has a 52-week-high of 92.37 and a 52-week-low of 13.69. At the end of the last trading period, Spirit AeroSystems Hldgs closed at $32.59. * For SM Energy Co (NYSE: SM), Stifel upgraded the previous rating of Hold to the current rating Buy. SM Energy earned $0.05 in the third quarter, compared to $0.11 in the year-ago quarter. The current stock performance of SM Energy shows a 52-week-high of 12.4 and a 52-week-low of 0.9. Moreover, at the end of the last trading period, the closing price was at $3.43. * Keefe, Bruyette & Woods upgraded the previous rating for Nasdaq Inc (NASDAQ: NDAQ) from Market Perform to Outperform. For the third quarter, Nasdaq had an EPS of $1.53, compared to year-ago quarter EPS of $1.27. At the moment, the stock has a 52-week-high of 139.5 and a 52-week-low of 71.66. Nasdaq closed at $124.76 at the end of the last trading period. * According to Goldman Sachs, the prior rating for Leggett & Platt Inc (NYSE: LEG) was changed from Neutral to Buy. Leggett & Platt earned $0.80 in the third quarter, compared to $0.76 in the year-ago quarter. The current stock performance of Leggett & Platt shows a 52-week-high of 53.235 and a 52-week-low of 22.03. Moreover, at the end of the last trading period, the closing price was at $43.26. * For Forterra Inc (NASDAQ: FRTA), Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Forterra earned $0.42 in the third quarter, compared to $0.34 in the year-ago quarter. The current stock performance of Forterra shows a 52-week-high of 17.5799 and a 52-week-low of 3.45. Moreover, at the end of the last trading period, the closing price was at $15.74. * Susquehanna upgraded the previous rating for Occidental Petroleum Corp (NYSE: OXY) from Neutral to Positive. Occidental Petroleum earned $0.84 in the third quarter, compared to $0.11 in the year-ago quarter. At the moment, the stock has a 52-week-high of 47.58 and a 52-week-low of 8.52. Occidental Petroleum closed at $13.37 at the end of the last trading period. * For Eagle Materials Inc (NYSE: EXP), Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. In the second quarter, Eagle Materials showed an EPS of $2.02, compared to $1.77 from the year-ago quarter. The current stock performance of Eagle Materials shows a 52-week-high of 97.79 and a 52-week-low of 41.83. Moreover, at the end of the last trading period, the closing price was at $92.72. * For Capri Holdings Ltd (NYSE: CPRI), BTIG upgraded the previous rating of Neutral to the current rating Buy. For the second quarter, Capri Holdings had an EPS of $0.90, compared to year-ago quarter EPS of $1.16. At the moment, the stock has a 52-week-high of 39.9 and a 52-week-low of 5.42. Capri Holdings closed at $33.35 at the end of the last trading period. * According to Canaccord Genuity, the prior rating for Astronics Corp (NASDAQ: ATRO) was changed from Hold to Buy. In the third quarter, Astronics showed an EPS of $0.17, compared to $0.00 from the year-ago quarter. At the moment, the stock has a 52-week-high of 30.64 and a 52-week-low of 6.2993. Astronics closed at $9.50 at the end of the last trading period. * For Schnitzer Steel Industries Inc (NASDAQ: SCHN), KeyBanc upgraded the previous rating of Sector Weight to the current rating Overweight. For the fourth quarter, Schnitzer Steel Indus had an EPS of $0.23, compared to year-ago quarter EPS of $0.42. At the moment, the stock has a 52-week-high of 25.1 and a 52-week-low of 10.09. Schnitzer Steel Indus closed at $23.89 at the end of the last trading period. * KeyBanc upgraded the previous rating for Cleveland-Cliffs Inc (NYSE: CLF) from Sector Weight to Overweight. Cleveland-Cliffs earned $0.04 in the third quarter, compared to $0.33 in the year-ago quarter. The stock has a 52-week-high of 9.34 and a 52-week-low of 2.63. At the end of the last trading period, Cleveland-Cliffs closed at $8.89. Downgrades * For WPX Energy Inc (NYSE: WPX), Stifel downgraded the previous rating of Buy to the current rating Hold. WPX Energy earned $0.11 in the third quarter, compared to $0.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of 14.425 and a 52-week-low of 1.94. WPX Energy closed at $6.92 at the end of the last trading period. * For Vulcan Materials Co (NYSE: VMC), Goldman Sachs downgraded the previous rating of Buy to the current rating Neutral. In the third quarter, Vulcan Materials showed an EPS of $1.56, compared to $1.68 from the year-ago quarter. The current stock performance of Vulcan Materials shows a 52-week-high of 153.88 and a 52-week-low of 65.56. Moreover, at the end of the last trading period, the closing price was at $140.20. * For Trane Technologies PLC (NYSE: TT), Goldman Sachs downgraded the previous rating of Buy to the current rating Neutral. For the third quarter, Trane Technologies had an EPS of $1.72, compared to year-ago quarter EPS of $1.99. At the moment, the stock has a 52-week-high of 153.72 and a 52-week-low of 70.0. Trane Technologies closed at $146.91 at the end of the last trading period. * According to Stifel, the prior rating for Tenaris SA (NYSE: TS) was changed from Buy to Hold. Tenaris earned $0.06 in the third quarter, compared to $0.18 in the year-ago quarter. The stock has a 52-week-high of 23.54 and a 52-week-low of 8.8616. At the end of the last trading period, Tenaris closed at $15.01. * BMO Capital downgraded the previous rating for Norbord Inc (NYSE: OSB) from Outperform to Market Perform. In the third quarter, Norbord showed an EPS of $2.52, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of 37.755 and a 52-week-low of 8.92. At the end of the last trading period, Norbord closed at $36.99. * According to Wedbush, the prior rating for Shake Shack Inc (NYSE: SHAK) was changed from Outperform to Neutral. For the third quarter, Shake Shack had an EPS of $0.11, compared to year-ago quarter EPS of $0.26. The stock has a 52-week-high of 86.985 and a 52-week-low of 30.01. At the end of the last trading period, Shake Shack closed at $78.38. * According to Goldman Sachs, the prior rating for Martin Marietta Materials Inc (NYSE: MLM) was changed from Buy to Neutral. For the third quarter, Martin Marietta Materials had an EPS of $3.84, compared to year-ago quarter EPS of $3.96. The stock has a 52-week-high of 281.82 and a 52-week-low of 135.08. At the end of the last trading period, Martin Marietta Materials closed at $269.71. * For Lennox International Inc (NYSE: LII), Goldman Sachs downgraded the previous rating of Neutral to the current rating Sell. In the third quarter, Lennox International showed an EPS of $3.53, compared to $3.34 from the year-ago quarter. At the moment, the stock has a 52-week-high of 319.77 and a 52-week-low of 163.395. Lennox International closed at $298.63 at the end of the last trading period. * For FireEye Inc (NASDAQ: FEYE), Barclays downgraded the previous rating of Equal-Weight to the current rating Underweight. FireEye earned $0.11 in the third quarter, compared to $0.02 in the year-ago quarter. The current stock performance of FireEye shows a 52-week-high of 18.34 and a 52-week-low of 7.54. Moreover, at the end of the last trading period, the closing price was at $14.24. * For Concho Resources Inc (NYSE: CXO), Stifel downgraded the previous rating of Buy to the current rating Hold. Concho Resources earned $1.43 in the third quarter, compared to $0.61 in the year-ago quarter. The stock has a 52-week-high of 93.34 and a 52-week-low of 33.13. At the end of the last trading period, Concho Resources closed at $57.22. * According to HSBC, the prior rating for Capri Holdings Ltd (NYSE: CPRI) was changed from Buy to Hold. For the second quarter, Capri Holdings had an EPS of $0.90, compared to year-ago quarter EPS of $1.16. The stock has a 52-week-high of 39.9 and a 52-week-low of 5.42. At the end of the last trading period, Capri Holdings closed at $33.35. * According to Goldman Sachs, the prior rating for Armstrong World Industries Inc (NYSE: AWI) was changed from Buy to Neutral. For the third quarter, Armstrong World Indus had an EPS of $1.07, compared to year-ago quarter EPS of $1.38. The stock has a 52-week-high of 111.46 and a 52-week-low of 57.96. At the end of the last trading period, Armstrong World Indus closed at $78.98. * According to Needham, the prior rating for Hologic Inc (NASDAQ: HOLX) was changed from Buy to Hold. In the fourth quarter, Hologic showed an EPS of $2.07, compared to $0.65 from the year-ago quarter. The stock has a 52-week-high of 77.488 and a 52-week-low of 26.49. At the end of the last trading period, Hologic closed at $70.01. * For Nucor Corp (NYSE: NUE), KeyBanc downgraded the previous rating of Overweight to the current rating Sector Weight. Nucor earned $0.67 in the third quarter, compared to $0.90 in the year-ago quarter. The stock has a 52-week-high of 58.7 and a 52-week-low of 27.525. At the end of the last trading period, Nucor closed at $52.83. Initiations * With a current rating of Outperform, Bernstein initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ: VRTX). The price target seems to have been set at $275.00 for Vertex Pharmaceuticals. In the third quarter, Vertex Pharmaceuticals showed an EPS of $2.64, compared to $1.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of 306.08 and a 52-week-low of 197.47. Vertex Pharmaceuticals closed at $211.97 at the end of the last trading period. * Piper Sandler initiated coverage on Penn National Gaming Inc (NASDAQ: PENN) with an Overweight rating. The price target for Penn National Gaming is set to $84.00. For the third quarter, Penn National Gaming had an EPS of $0.93, compared to year-ago quarter EPS of $0.38. At the moment, the stock has a 52-week-high of 76.62 and a 52-week-low of 3.75. Penn National Gaming closed at $70.50 at the end of the last trading period. * Cantor Fitzgerald initiated coverage on Ocuphire Pharma Inc (NASDAQ: OCUP) with an Overweight rating. The price target for Ocuphire Pharma is set to $15.00. The current stock performance of Ocuphire Pharma shows a 52-week-high of 6.48 and a 52-week-low of 5.07. Moreover, at the end of the last trading period, the closing price was at $5.72. * Loop Capital initiated coverage on Nikola Corp (NASDAQ: NKLA) with a Buy rating. The price target for Nikola is set to $35.00. In the third quarter, Nikola earned $0.16. The current stock performance of Nikola shows a 52-week-high of 93.99 and a 52-week-low of 16.15. Moreover, at the end of the last trading period, the closing price was at $26.23. * With a current rating of Overweight, Piper Sandler initiated coverage on DraftKings Inc (NASDAQ: DKNG). The price target seems to have been set at $58.00 for DraftKings. Interestingly, in the third quarter, DraftKings's EPS was $0.98. At the moment, the stock has a 52-week-high of 64.19 and a 52-week-low of 18.0. DraftKings closed at $49.32 at the end of the last trading period. * With a current rating of Outperform, Oppenheimer initiated coverage on Cannae Holdings Inc (NYSE: CNNE). The price target seems to have been set at $49.00 for Cannae Holdings. In the third quarter, Cannae Holdings showed an EPS of $1.44, compared to $0.64 from the year-ago quarter. At the moment, the stock has a 52-week-high of 44.87 and a 52-week-low of 20.51. Cannae Holdings closed at $39.96 at the end of the last trading period. * Bernstein initiated coverage on Alexion Pharmaceuticals Inc (NASDAQ: ALXN) with a Market Perform rating. The price target for Alexion Pharmaceuticals is set to $148.00. Alexion Pharmaceuticals earned $3.24 in the third quarter, compared to $2.79 in the year-ago quarter. The current stock performance of Alexion Pharmaceuticals shows a 52-week-high of 128.57 and a 52-week-low of 72.67. Moreover, at the end of the last trading period, the closing price was at $122.05.See more from Benzinga * Click here for options trades from Benzinga * RMR Group: Q4 Earnings Insights * 12 Energy Stocks Moving In Friday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/20 14:32
New formulation of Alexion's Ultomiris Ok'd in Europe for rare blood disease and kidney disorder
The European Commission has granted marketing authorization to Alexion Pharmaceuticals' (ALXN) Ultomiris (ravulizumab-cwvz) 100 mg/mL intravenous formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria ((PNH)), a rare blood disease in which the immune system destroys
Seekingalpha · 11/20 11:00
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Business Wire · 11/20 07:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALXN. Analyze the recent business situations of Alexion Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALXN stock price target is 145.35 with a high estimate of 179.00 and a low estimate of 119.00.
EPS
Institutional Holdings
Institutions: 1.04K
Institutional Holdings: 211.60M
% Owned: 96.69%
Shares Outstanding: 218.85M
TypeInstitutionsShares
Increased
255
15.32M
New
141
-1.66M
Decreased
256
15.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.36%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
David Brennan
Chief Executive Officer/Director
Ludwig Hantson
Chief Financial Officer/Executive Vice President
Aradhana Sarin
Executive Vice President/Chief Compliance Officer
Indrani Franchini
Executive Vice President/Secretary
Ellen Chiniara
Executive Vice President
Tanisha Carino
Executive Vice President
Brian Goff
Executive Vice President
John Orloff
Other
Becky Lillie
Other
Uzair Qadeer
Independent Director
Felix Baker
Independent Director
Christopher Coughlin
Independent Director
Deborah Dunsire
Independent Director
Paul Friedman
Independent Director
John Mollen
Independent Director
Francois Nader
Independent Director
Judith Reinsdorf
Independent Director
Andreas Rummelt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALXN
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.